COVID-19

One of the monoclonal antibodies in the therapeutic Evusheld has been computationally redesigned to restore its action against Omicron variants of the virus that causes COVID-19. Read More

Dr. James Crowe Jr., director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center, led the team that discovered a monoclonal antibody combination that protects against COVID-19. Optimized and developed by AstraZeneca, the monoclonal antibody combination called  Evusheld is the first treatment… Read More

James Crowe Jr., MD, director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center, has received the Building the Foundation Award from Research!America, a national biomedical research advocacy organization, for his team’s role in developing human monoclonal antibodies and vaccine candidates against COVID-19. The award, which was announced Oct. 6,… Read More

Vanderbilt University Medical Center has been awarded a nearly $8 million grant from the National Institutes of Health to construct a state-of-the-art BioSafety Level 3 (BSL3) facility for research involving the COVID-19 virus, anthrax and other dangerous microorganisms. VUMC currently has two BSL3 labs, but they are small, outdated and… Read More

The virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism. The results of the laboratory study led by researchers at Vanderbilt University Medical Center and published April 28 in the journal Science… Read More

The virus that causes COVID-19 can develop partial resistance to the antiviral drug remdesivir during infection of cultured cells in the laboratory by more than one mechanism. The results of the laboratory study led by researchers at Vanderbilt University Medical Center and published April 28 in the journal Science… Read More

James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, and Michel Nussenzweig, MD, PhD, of The Rockefeller University, have been jointly awarded the 2022 Harrington Prize for Innovation in Medicine for “groundbreaking work” that enabled the use of human antibodies to treat COVID-19. The announcement was made… Read More

Seth Zost, PhD, a research fellow in the laboratory of James E. Crowe Jr., MD, director of the Vanderbilt Vaccine Center, has been awarded a major international prize for his research on COVID-19 and other life-threatening viral diseases. The Claude Hannoun Prize for Best Body of Work is… Read More